Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab after surgical resection for Crohn's disease
2022-002389-33Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Guselkumab with Placebo (2 arms). Primary endpoint: Endoscopic recurrence. Started Dec 2022; status: completed.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-002389-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002389-33.